TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, announced the appointment of Greg Mayes as President and Chief Executive Officer.


Previous articleMindMed Announces Pricing of Public Offering of Common Shares and Warrants
Next articlePharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022